title: Applicability of histoculture drug response assays in colorectal cancer chemotherapy.
abstract: OBJECTIVE
  The present study, using the histoculture drug response assay (HDRA) compared chemosensitivity with the clinical response of a treatment regime in patients with advanced colorectal cancer (CRC).
  
  
  METHODS
  A total of 324 patients with primary CRC were prospectively enrolled. HDRAs were performed using seven combinations of anticancer drugs, including 5-fluorouracil with leucovorin (FL), FL with oxaliplatin (FOLFOX), irinotecan (FOLFIRI), and their combinations with bevacizumab and cetuximab.
  
  
  RESULTS
  Among 324 HDRA results, tumor inhibition rates of regimes using FOLFOX (34.2-39.2%) were higher than those using FOLFIRI (24.2-32.7%, p<0.001). Out of 86 evaluated chemotherapeutic regimes, the correlation rate of HDRA to the clinical effect of chemotherapy was calculated to be 66.3% (57/86), with a 72.7% (40/55) sensitivity and a 54.7% (17/31) specificity.
  
  
  CONCLUSIONS
  HDRA might be a feasible and useful technique for predicting therapy efficacy and selecting the appropriate anticancer regime for individual patients, notwithstanding its low accuracy.
authors: Department of Surgery, University of Ulsan College of Medicine, 86 Asanbyeongwon-gil, Songpa-gu, Seoul 138-736, Korea.
authors: Yong Sik
authors: YS
authors: Yoon
authors: Chan Wook
authors: CW
authors: Kim
authors: Seon Ae
authors: SA
authors: Roh
authors: Dong Hyung
authors: DH
authors: Cho
authors: Gyu Pyo
authors: GP
authors: Kim
authors: Yong Sang
authors: YS
authors: Hong
authors: Tae Won
authors: TW
authors: Kim
authors: Moon Bo
authors: MB
authors: Kim
authors: Jin Cheon
authors: JC
authors: Kim
mesh_terms: D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D015179:Colorectal Neoplasms / Q000188:drug therapy*; D004354:Drug Screening Assays, Antitumor; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D014407:Tumor Cells, Cultured